EQUITY METHOD INVESTMENT	6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
EQUITY METHOD INVESTMENT	EQUITY METHOD INVESTMENT On February 21, 2022, Arteris IP (Hong Kong) Ltd. (AHK), a wholly-owned subsidiary of the Company, entered into a Share Purchase and Shareholders Agreement (the SPA) with certain investors and Ningbo Transchip Information Consulting Partnership (Limited Partnership) (Management Co), pursuant to which, the Company, certain investors and Management Co subscribed to the registered capital of Transchip Technology (Nanjing) Co., Ltd. (Transchip). In September 2025, Transchip entered into a convertible bond investment agreement along with certain investors, under which Transchip received approximately $5.6 million as a loan in October 2025. During the three months ended June 30, 2026, $4.4 million of the loan was converted into Transchip’s equity. The Company did not provide funding under this agreement. In addition, Transchip granted stock awards to certain of its employees in February 2026. As a result of these transactions, the Company’s ownership of Transchip’s registered capital based on issued and outstanding shares decreased from 42.7% as of December 31, 2025 to 33.8% as of June 30, 2026, and the Company’s ownership interest of Transchip’s registered capital reduced from 35.0% as of December 31, 2025 to 32.2% on a fully diluted basis as of June 30, 2026. No additional losses were recognized for the three months ended June 30, 2026 as the carrying value associated with the equity method investment in Transchip was zero as of June 30, 2026. The Company’s loss from its proportionate share of its equity method investment in Transchip was $0.8 million for the three months ended June 30, 2025, and $3.0 million and $1.6 million for the six months ended June 30, 2026 and 2025, respectively.

EQUITY METHOD INVESTMENT

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

On February 21, 2022, Arteris IP (Hong Kong) Ltd. (AHK), a wholly-owned subsidiary of the Company, entered into a Share Purchase and Shareholders Agreement (the SPA) with certain investors and Ningbo Transchip Information Consulting Partnership (Limited Partnership) (Management Co), pursuant to which, the Company, certain investors and Management Co subscribed to the registered capital of Transchip Technology (Nanjing) Co., Ltd. (Transchip).

In September 2025, Transchip entered into a convertible bond investment agreement along with certain investors, under which Transchip received approximately $5.6 million as a loan in October 2025. During the three months ended June 30, 2026, $4.4 million of the loan was converted into Transchip’s equity. The Company did not provide funding under this agreement. In addition, Transchip granted stock awards to certain of its employees in February 2026. As a result of these transactions, the Company’s ownership of Transchip’s registered capital based on issued and outstanding shares decreased from 42.7% as of December 31, 2025 to 33.8% as of June 30, 2026, and the Company’s ownership interest of Transchip’s registered capital reduced from 35.0% as of December 31, 2025 to 32.2% on a fully diluted basis as of June 30, 2026.

No additional losses were recognized for the three months ended June 30, 2026 as the carrying value associated with the equity method investment in Transchip was zero as of June 30, 2026. The Company’s loss from its proportionate share of its equity method investment in Transchip was $0.8 million for the three months ended June 30, 2025, and $3.0 million and $1.6 million for the six months ended June 30, 2026 and 2025, respectively.